阿德福韦酯联合香菇多糖治疗慢性乙型肝炎肝纤维化的疗效观察

Therapeutic Effect of Lentinan in Combination With Adefovir Dipivoxil on Liver Fibrosis in Chronic Hepatitis B Patients

目的观察香茹多糖联合阿德福韦酯(ADV)对慢性乙肝肝纤维化的疗效。方法将符合条件的慢性乙肝患者随机分为香茹多糖加ADV联合治疗组和ADV单一治疗组,疗程半年,观察治疗前后HBV DNA滴度、血清肝纤维化4项指标和超声影像学等指标变化。结果两组治疗后上述指标均较治疗前下降,且联合治疗组较单一治疗组改善更为明显,尤以HA、PⅢNP、IV-C、LN和门静脉血流速度等指标改善更明显(P<0.05,P<0.01)。结论ADV可改善慢性乙肝纤维化,而香茹多糖可有效增强ADV抗肝纤维化的疗效。

Objective To observe the influence of lentinan （LET） in combination with adefovir dipivoxil （ADV） on hver fibrosis indexes in hepatitis B e antigen positive adults with chronic hepatitis B. Methods Patients with chronic hepatitis B were randomly assigned to receive the treatment with adefovir or adefovir plus lentinan for a minimum of six months. The parameters, including diameter of portal vein and splenic vein （ Dpv and Dsv ）, speed of blood flow in portal vein （Spv ） as well as liver fibrosis indexes, such as hyaluronic acid （ HA ）, the procollagen type ⅢN - terminal propeptide （P ⅢNP）, type Ⅳcollagen （ Ⅳ-C） and laminin （LN）, were determined before and after treatment. Results The above mentioned parameters in the post -treatment was improved, compared with in the pro -treatment. Furthermore, after treatment the improvement in combination group was significantly superior to that in the ADV monotherapy group, especially the makers of HA, PⅢ NP, Ⅳ - C, LN and Spy. Conclusions Adefovir dipivoxil could improve the liver fibrosis in the chronic hepatitis B. Lentinan could efficiently enhance the anti - fibrotic effect of ADV on liver fibrosis of chronic hepatitis B patients.